

### **Product datasheet for TR304009**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

### **ARFBP1 (HUWE1) Human shRNA Plasmid Kit (Locus ID 10075)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** ARFBP1 (HUWE1) Human shRNA Plasmid Kit (Locus ID 10075)

**Locus ID:** 10075

Synonyms: ARF-BP1; HECTH9; HSPC272; Ib772; LASU1; MRXST; MULE; URE-B1; UREB1

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection: Format:

Retroviral plasmids

Components: HUWE1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

10075). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

**RefSeq:** NM 005703, NM 031407, NM 031407.1, NM 031407.2, NM 031407.3, NM 031407.4,

NM 031407.6, BC002602, BC018750, BC038184, BC063505, BC072421, BC107576

UniProt ID: Q7Z6Z7

Summary: This gene encodes a protein containing a C-terminal HECT (E6AP type E3 ubiquitin protein

ligase) domain that functions as an E3 ubiquitin ligase. The encoded protein is required for the ubiquitination and subsequent degradation of the anti-apoptotic protein Mcl1 (myeloid cell leukemia sequence 1 (BCL2-related)). This protein also ubiquitinates the p53 tumor suppressor, core histones, and DNA polymerase beta. Mutations in this gene are associated with Turner type X-linked syndromic cognitive disability. [provided by RefSeq, Aug 2013]

**shRNA Design:** These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.



#### ARFBP1 (HUWE1) Human shRNA Plasmid Kit (Locus ID 10075) - TR304009

# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).